杨卡

杨卡博士本科毕业于天津大学，随后在威斯康星大学麦迪逊分校获得博士学位，并先后在威斯康星大学麦迪逊分校、圣裘德儿童研究医院及哈佛医学院从事博士后研究。2026年6月全职加入深圳湾实验室，任化学生物学研究所特聘研究员。

难成药蛋白缺乏明确的可配体位点、动态调控规律和有效干预工具，是创新药物发现的重要瓶颈。围绕“如何在蛋白质组尺度发现小分子可调控的功能位点并干预蛋白稳态”，杨卡课题组形成了“位点发现-机制解析-化学调控”的研究策略。通过应用包括高通量化学蛋白质组学、靶向蛋白降解和生物信息学等技术，课题组重点攻关寻找和验证新的药物靶点/位点，探索难成药靶点可配体性以及发现具有治疗疾病的活性小分子。

杨卡博士以独立一作或共同一作（排名第一）在Cell Chemical Biology、ACS Chemical Biology等国际期刊发表研究论文7篇，并以共同一作（排名二至四）在Cell、Nature Communications、Journal of Medicinal Chemistry等国际期刊发表研究论文7篇，部分成果曾被综述期刊Nature Reviews Drug Discovery给予高亮点评。此外，其还以共同作者在Nature Chemical Biology、Nature Communications、Molecular Neurodegeneration等期刊发表论文20篇。申请人工作五年内引用超1400次，h指数（h-index）达到17（数据来源Google Scholar）。相关工作已获2项美国专利授权。

代表成果

代表文章：

1. Yang K*, Li S, Li B, Richards DM, Dong K, Seneviratne U, Lee W, Iannetta A, Xu H, Gygi P, Qing Y*. Analysis of Confounding Factors in Reactive Cysteine Profiling Reveals Enhanced Chromatin Protein Binding via CDK7 Inhibition by THZ1. ACS Chem. Biol. 2026 (Published ASAP)

2. Li W§, Dasgupta A^§, Yang K^§, …, Peng J^⁎, Liu Y^⁎. Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions. Cell. 2025. 188:1

3. Yarbro JM^§, Han X^§, Dasgupta A^§, Yang K^§, …, Peng J^⁎. Human and mouse proteomics reveals the shared pathways in Alzheimer’s disease and delayed protein turnover in the amyloidome. Nature Communication. 2025. 16:1533

4. Yang K, Paulo JA, Gygi SP, Yu Q^⁎. Enhanced Sample Multiplexing-Based Targeted Proteomics with Intelligent Data Acquisition. Journal of the American Society for Mass Spectrometry. 2024. 35: 2420

5. Yang K, Whitehouse RL, Dawson SL, Zhang L, Martin JG, Johnson DS, Paulo JA, Gygi SP^⁎, Yu Q^⁎. Accelerating multiplexed profiling of protein-ligand interactions: High-throughput plate-based reactive cysteine profiling with minimal input. Cell Chemical Biology. 2024. 31:565. Highlighted by Nature Review Drug Discovery. 2024. 23:103.

6. Xie H^§, Yang K^§, Winston-McPherson G, Stapleton D, Keller M, Attie A, Smith K, Tang W^⁎. From Methylene Bridged Diindole to Carbonyl Linked Benzimidazoleindole: Development of Potent and Metabolically Stable PCSK9 Modulators. Eur. J. Med. Chem. 2020. 206: 112678

7. Yang K^§, Zhao Y^§, Nie X, Wu H, Wang B, Almodovar-Rivera CM, Xie H^⁎, Tang W^⁎. Development of a Cell-based Target Engagement Assay for the Identification of Cell-Permeable Cereblon E3 Ubiquitin Ligase Ligands and Their Application in Targeted Protein Degradation. Cell Chem. Biol. 2020. 27: 866-876

8. Yang K^§, Wu, H^§, Zhang, Z, Leisten ED, Nie X, Liu B, Wen Z, Zhang J, Cunningham MD, Tang W⁎. Development of Selective Histone Deacetylase 6 (HDAC6) Degrad-ers Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase. ACS Med. Chem. Lett. 2020, 11, 4: 575-581

9. Wu H^§, Yang K^§, Zhang Z, Leisten ED, Li Z, Xie H, Liu J, Tang W^⁎. Development of Multi-Functional HDAC6 Degraders with Potent Anti-Myeloma Activity. J. Med. Chem. 2019, 621: 7042-7057.

10. Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W^⁎. Development of The First Small Molecule Histone Deacetylase 6 (HDAC6) Degraders. Bioorg. Med. Chem. Lett. 2018. 28(14): 2493-2497.